Stockscreener 앱 받기
3.69
12.16%
0.40
시간 외 거래:
3.67
-0.02
-0.54%
전일 마감가:
$3.29
열려 있는:
$3.05
하루 거래량:
1.35M
Relative Volume:
3.61
시가총액:
$183.14M
수익:
$230.47M
순이익/손실:
$30.28M
주가수익비율:
6.0492
EPS:
0.61
순현금흐름:
$38.86M
1주 성능:
+20.20%
1개월 성능:
+2.79%
6개월 성능:
+32.73%
1년 성능:
-3.66%
1일 변동 폭
$3.05
$3.7525
1주일 범위
$3.04
$3.7525
52주 변동 폭
$2.225
$4.06
Puma Biotechnology Inc Stock (PBYI) Company Profile
명칭
Puma Biotechnology Inc
전화
(424) 248-6500
주소
10880 WILSHIRE BLVD., LOS ANGELES, CA
PBYI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.69 | 161.32M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Underperform |
| 2019-10-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-10 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-01-17 | 개시 | Leerink Partners | Mkt Perform |
| 2019-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-11-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-11-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 개시 | Goldman | Sell |
| 2018-05-11 | 재확인 | Stifel | Buy |
| 2017-11-10 | 재확인 | Citigroup | Buy |
| 2017-11-10 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 재확인 | Stifel | Buy |
| 2017-09-11 | 재확인 | Credit Suisse | Outperform |
| 2017-07-10 | 재개 | Leerink Partners | Outperform |
| 2017-06-06 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 재확인 | RBC Capital Mkts | Sector Perform |
모두보기
Puma Biotechnology Inc 주식(PBYI)의 최신 뉴스
Why is Puma Biotechnology Inc. stock going downStock Picks with Accelerated Return - kangso.co.kr
Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript - Insider Monkey
Puma Biotechnology 2025 Q2 Earnings Profitability Returns with 229.3% Net Income Surge - AInvest
Puma Biotechnology's Q2 Earnings Outperformance and Nerlynx Momentum Signal a Strategic Buy Opportunity - AInvest
Puma Biotechnology Awards Nearly 28,000 Shares to Three New Employees Under Nasdaq Rule - Stock Titan
Puma Biotechnology Q2 2025 slides: NERLYNX revenue grows 14% quarter-over-quarter - Investing.com India
Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast - Investing.com
Puma Biotechnology Flips To Profit On Cancer Drug Sales - Finimize
Puma Biotechnology Inc (PBYI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Puma Biotechnology 2025 Q2 Earnings Strong Performance as Net Income Surges 229.3% - AInvest
Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials - MSN
Puma Biotechnology Reports Second Quarter 2025 Financial Results - BioSpace
Puma Biotechnology Reports Strong Q2 2025 Results - TipRanks
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotechnology: Hold Rating Amid Stable Q2 Performance and Uncertain Trial Outcomes - TipRanks
Puma Biotechnology's Q2 2025: Key Contradictions in Alisertib Strategy, In-Licensing, and Sales Growth - AInvest
Puma Biotech: Q2 Earnings Snapshot - San Francisco Chronicle
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Puma Biotechnology files Form 8-K regarding Q2 2025 results - Stock Titan
Puma Biotechnology Reports Second Quarter Financial Results - Yahoo Finance
Screener Results Flag Puma Biotechnology Inc. as OversoldGrowth Based Investment Plan Guidance Highlighted - metal.it
What are the latest earnings results for Puma Biotechnology Inc.Get professional advice for portfolio optimization - Jammu Links News
How volatile is Puma Biotechnology Inc. stock compared to the marketInvest in high-yield stocks with confidence - Jammu Links News
What drives Puma Biotechnology Inc. stock priceDiscover high-impact stocks for growth - Jammu Links News
How strong is Puma Biotechnology Inc. company’s balance sheetAchieve consistent profits with proven methods - Jammu Links News
What are analysts’ price targets for Puma Biotechnology Inc. in the next 12 monthsFree Market Volatility Navigation Tips - Jammu Links News
What makes Puma Biotechnology Inc. stock price move sharplyOutstanding capital growth - Jammu Links News
What catalysts could drive Puma Biotechnology Inc. stock higher in 2025Tremendous wealth creation - Jammu Links News
Is Puma Biotechnology Inc. a good long term investmentStay ahead with daily market updates - Jammu Links News
What analysts say about Puma Biotechnology Inc. stockInvest confidently with professional market insights - Jammu Links News
What are Puma Biotechnology Inc. company’s key revenue driversUnlock powerful portfolio optimization tools - Jammu Links News
What is the dividend policy of Puma Biotechnology Inc. stockRobust financial gains - Jammu Links News
Is Puma Biotechnology Inc. stock overvalued or undervaluedDiscover market opportunities with expert help - Jammu Links News
Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago - Yahoo Finance
Volatility clustering patterns for Puma Biotechnology Inc.Daily Breakout List with Smart Filters - Newser
How sentiment analysis helps forecast Puma Biotechnology Inc.Free Fast Entry High Potential Stock Alerts - Newser
How to monitor Puma Biotechnology Inc. with trend dashboardsShort-Term Stock Trend Forecast Guide - Newser
How to use a screener to detect Puma Biotechnology Inc. breakoutsAI Stock Movement Forecast with Accuracy - Newser
Does Puma Biotechnology Inc. stock pay reliable dividendsBeginner Friendly Stock Selection Guide Updated - metal.it
Why Puma Biotechnology Inc. stock attracts strong analyst attentionEarly Entry Tips With Low Risk Zone Shared - metal.it
Predicting Puma Biotechnology Inc. trend using moving averagesWeekly Trend Watch with Market Signals - Newser
Can volume confirm reversal in Puma Biotechnology Inc.Daily Market Momentum Summary and Strategy - Newser
Signal strength of Puma Biotechnology Inc. stock in tech scannersFree Safe Entry Stock Watch Suggestions - Newser
Puma Biotechnology Inc. stock trend forecastTop Stock Picks with Forecast Accuracy - Newser
Trend Reversal Possible in Puma Biotechnology Inc. Charts IndicateMarket Entry and Exit Point Tips From Traders - metal.it
Quant Funds Rotate Into Puma Biotechnology Inc. StockConsistent Income Focused Trade List Analyzed - metal.it
Puma Biotechnology Inc (PBYI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):